These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeted therapies in metastatic renal cancer in 2009. Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565 [TBL] [Abstract][Full Text] [Related]
3. An update on targeted therapy in metastatic renal cell carcinoma. Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985 [TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075 [TBL] [Abstract][Full Text] [Related]
5. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394 [TBL] [Abstract][Full Text] [Related]
6. Signaling inhibitors in metastatic renal cell carcinoma. Escudier B Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338 [TBL] [Abstract][Full Text] [Related]
7. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011 [TBL] [Abstract][Full Text] [Related]
8. Trials probe new agents for kidney cancer. Hampton T JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411 [No Abstract] [Full Text] [Related]